Cover Image
市場調查報告書

非小細胞肺癌:治療法與創新的免疫療法--市場專家(KOL)考察

Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insight

出版商 FirstWord 商品編碼 298207
出版日期 內容資訊 英文 134 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非小細胞肺癌:治療法與創新的免疫療法--市場專家(KOL)考察 Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insight
出版日期: 2014年03月24日 內容資訊: 英文 134 Pages
簡介

非小細胞肺癌開發了創紀錄的治療法,預計馬上就能一般使用。新型免疫療法、個人化治療選擇擴大、醫藥品開發進展活動將在不遠的未來同時進行。

本報告針對非小細胞肺癌(NSCLC)治療藥物市場最新動向與未來展望分析提供業界主要創業領導(KOL:市場專家)12名問卷調查、已上市/治療中醫藥品概要、今後技術開發□市場成長預測,目錄介紹如下。

摘要

分析目的

分析焦點

EGFR突變陽性

  • 概要
    • 重要治療資料
    • 受矚目的主要治療
  • 已上市醫藥品
    • Tarceva(erlotinib:Roche/Astellas)
    • Iressa(gefitinib; AstraZeneca)
    • Gilotrif(afatinib; Boehringer Ingelheim)
  • 臨床藥品
    • PF-00299804(dacomitinib; Pfizer/SFJ Pharmaceuticals)
    • Necitumumab(Eli Lilly)
    • CO-1686(Clovis Oncology, Inc)
  • EGFR突變陽性現在□未來治療法則

EML4-ALK陽性

  • 概要
    • 重要治療資料
    • 受矚目的主要治療
  • 已上市醫藥品
    • Xalkori(ヱэМХЯй:Pfizer)
  • 臨床醫藥品
    • LDK378(Novartis)
  • EML4-ALK陽性現在□未來治療法則

EML4-ALK與EGFR突變陽性

  • 概要
    • 重要治療資料
    • 受矚目的主要治療
  • 已上市醫藥品
    • Avastin(bevacizumab; Roche/Genentech/Chugai)
    • Alimta(pemetrexed; Eli Lilly)
  • 臨床醫藥品
    • Nintedanib(BIBF 1120; Boehringer Ingelheim)
    • Cyramza(ramucirumab/IMC-1121B; Eli Lilly)
    • Votrient(pazopanib; GlaxoSmithKline)
    • Halaven(eribulin; Eisai)
    • AZD6244(selumetinib; AstraZeneca)
    • ARQ 197(tivantinib; ArQule/Daiichi Sankyo/Kyowa Hakko Kirin)
  • EML4-ALK與EGFR突變陽性現在□未來治療法則

免疫療法

  • 概要
    • 受矚目的主要治療
  • 臨床醫藥品
    • Nivolumab(BMS-936558:Bristol-Myers Squibb/小野藥品工業)
    • MK-3475(Merck & Co.)
    • RG7446(Roche)
    • GSK1572932A(MAGE-A3 ASCI:GlaxoSmithKline/Agenus)
    • Yervoy(ipilimumab; Bristol-Myers Squibb)
    • L-BLP25(tecemotide; Merck KGaA)
  • 免疫療法未來治療法則

附錄

  • 市場專家(KOL)簡歷(北美□歐洲)
目錄

Change is coming to the NSCLC treatment algorithm-and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices and further drug developments are all set to roll out in the near future. What are the potential blockbusters, who will gain approvals first and what are the future challenges?

Drivers of change

  • Revolutionary immunotherapies. From cancer vaccines to checkpoint inhibitors, several therapies in late-stage development are due to launch very soon. According to KOLs interviewed, the most promising are programmed cell death protein 1 (PD-1) pathway inhibitors. The race is on between Bristol-Myers Squibb's nivolumab, Merck & Co.'s MK-3475 and Roche's RG7446 to become the first to be approved.
  • Mutation analysis. Personalised targeted therapy has been a paradigm shift towards assessing patients' treatment based on mutation status. Leading the way is Xalkori (crizotinib; Pfizer) with its associated Anaplastic Lymphoma Kinase (ALK)-testing diagnostic-yet it faces pending competition from several other therapies in early- to late-stage development.
  • Key opportunities in EGFR resistance. Since patients all develop resistance to currently marketed EGFR inhibitors, significant opportunities exist in developing a therapy to tackle the T790 mutation responsible for approximately half of acquired resistance cases. While pipeline therapies have not yet proven they have the answer, KOLs believe early phase 1 results from Clovis's CO-1686 position it well.

Unique insider clinical opinion

Comprehensive, concise and offering rare access to the most forward-thinking KOL analysis of NSCLC treatments, development and competition, KOL Insight: Non-small cell lung cancer is an essential tool for keeping abreast of events that will shape the future.

Based on in-depth interviews with 12 experienced and highly-regarded KOLs across North America and Europe, the report provides the latest insights into the current and future treatment landscapes. Chosen for their unique abilities, clinical experience, publications and treatment guideline development as well as presence on the international stage, the KOLs bring incisive, real-world analysis of NSCLC treatment.

Pressing issues and questions:

  • Which drug attributes create a first- and subsequent-line treatment preference for patients who are EGFR mutation positive, EML4-ALK translocation positive and EGFR mutation/ EML4-ALK translocation negative?
  • How are current targeted NSCLC therapies perceived by clinicians in terms of efficacy, tolerability, ease of administration, and other product attributes?
  • Which recently completed or ongoing clinical trials have the greatest potential to impact the future treatment of NSCLC, e.g. the REVEL, SELECT-1, MAGRIT, LUME LUNG 1, ARCHER 1050 and CheckMate 057 trials?
  • What do pipeline NSCLC targeted therapies need to show in order to become the treatment of choice in a specific patient segment and line of therapy?
  • How will the use of each current and pipeline NSCLC product change in the future in terms of patient segment, line of therapy and preference?

Key benefits:

Developments in the treatment of NSCLC are progressing rapidly. In KOL Insight: Non-small cell lung cancer, you will:

  • Gain an invaluable overview into the most dynamic areas of the NSCLC market
  • Understand the role of Pfizer's Xalkori in mutation analysis and personalised treatment therapy
  • Obtain insight into why KOLs view EGFR resistance as the largest opportunity for developers-and why Clovis's CO-1686 may be well-positioned
  • Understand why competition will grow in first- and second-line settings for Avastin and Alimta

This report will allow you to:

  • View the spectrum of NSCLC treatments and KOL opinion of emerging clinical data
  • Analyse current and future treatment algorithms
  • Identify promising late-stage drug developments
  • Track KOL opinion continuously over the next 12 months
  • Understand which drugs are most vulnerable to competition and which upcoming therapies will address unmet needs

Key benefits

  • Gain an invaluable overview into the most dynamic areas of the NSCLC market
  • Understand the role of Pfizer's Xalkori in mutation analysis and personalised treatment therapy
  • Obtain insight into why KOLs view EGFR resistance as the largest opportunity for developers-and why Clovis's CO-1686 may be well-positioned
  • Understand why competition will grow in first- and second-line settings for Avastin and Alimta

This report will allow you to:

  • View the spectrum of NSCLC treatments and KOL opinion of emerging clinical data
  • Analyse current and future treatment algorithms
  • Identify promising late-stage drug developments
  • Track KOL opinion continuously over the next 12 months
  • Understand which drugs are most vulnerable to competition and which upcoming therapies will address unmet needs

Essential intelligence for:

  • Competitive Intelligence
  • Market Research
  • Business Development & Licensing
  • Brand Teams
  • Marketing Excellence
  • New Product Planning/Commercialisation Teams
  • Forecasting and Market Analytics
  • Medical Affairs
  • Market Access

Table of Contents

Executive summary

Research Objectives

Research Focus

EGFR mutation positive

  • Overview
    • Pivotal trial data
    • Key trials to watch
  • Marketed drugs
    • Tarceva (erlotinib; Roche/Astellas)
    • Iressa (gefitinib; AstraZeneca)
    • Gilotrif (afatinib; Boehringer Ingelheim)
  • Pipeline drugs
    • PF-00299804 (dacomitinib; Pfizer/SFJ Pharmaceuticals)
    • Necitumumab (Eli Lilly)
    • CO-1686 (Clovis Oncology, Inc)
  • EGFR mutation positive current and future treatment algorithm

EML4-ALK positive

  • Overview
    • Pivotal trial data
    • Key trials to watch
  • Marketed drugs
    • Xalkori (crizotinib; Pfizer)
  • Pipeline drugs
    • LDK378 (Novartis)
  • EML4-ALK positive current and future treatment algorithm

EML4-ALK and EGFR mutation negative

  • Overview
    • Pivotal trial data
    • Key trials to watch
  • Marketed drugs
    • Avastin (bevacizumab; Roche/Genentech/Chugai)
    • Alimta (pemetrexed; Eli Lilly)
  • Pipeline drugs
    • Nintedanib (BIBF 1120; Boehringer Ingelheim)
    • Cyramza (ramucirumab/IMC-1121B; Eli Lilly)
    • Votrient (pazopanib; GlaxoSmithKline)
    • Halaven (eribulin; Eisai)
    • AZD6244 (selumetinib; AstraZeneca)
    • ARQ 197 (tivantinib; ArQule/Daiichi Sankyo/Kyowa Hakko Kirin)
  • EML4-ALK and EGFR mutation negative current and future treatment algorithm

Immunotherapy

  • Overview
    • Key trials to watch
  • Pipeline drugs
    • Nivolumab (BMS-936558; Bristol-Myers Squibb/Ono Pharmaceuticals)
    • MK-3475 (Merck & Co.)
    • RG7446 (Roche)
    • GSK1572932A (MAGE-A3 ASCI; GlaxoSmithKline/Agenus)
    • Yervoy (ipilimumab; Bristol-Myers Squibb)
    • L-BLP25 (tecemotide; Merck KGaA)
  • Immunotherapy future treatment algorithm

Appendix

  • KOL biographies
    • KOLS from North America
    • KOLs from Europe
Back to Top